LRIG1 qPCR Primer Pairs, Mouse 基本信息
Target Details
Product Details
Component:
1 vial of lyophilized qPCR primer mix (1 nmol each primer, sufficient for 200 numbers of 25 μl reactions).
QPCR Primer Description:
Verified forward and reverse primers for analyzing the quantitative expression of gene.
Application & Quality
应用:
SYBR® Green-based quantitative real-time PCR (qPCR).
质控:
The primer mix has been verified to generate satisfactory qPCR data on Roche Applied-science LightCycler® 480 Ⅱ.
储存 & 运输
运输:
Lyophilized qPCR primer mix is shipped at ambiente temperatura
储存:
The lyophilized product is stable for one year from date of receipt when stored at -20℃. The suspended product is stable for six months from date of receipt when stored at -20℃.
***Sino biological qEASY qPCR primer pairs are used for SYBR Green-based real-time RT-PCR, The primers are designed by using SBI's proprietary primer design algorithm. Our primer collection covers the entire human genomes. It can be widely applied in the quantitative analysis of gene expression.***
Features and Advantages
Unique Primer Design
To avoid genomic DNA amplification, at least one primer is designed crosses the junction of exons according to the conserved region of a specific gene with all variants.
Strict Validation Process
Confirmed in positive organizations; screened the primer with high specificity and high sensitivity.
Uniform PCR conditions, Saving time and cost
~100% amplification curve, ensuring the accuracy of the RNA quantitative
LRIG1 qPCR Primer Pairs, Mouse Alternative Names
D6Bwg0781e qPCR Primer Pairs, Mouse;Img qPCR Primer Pairs, Mouse;LIG-1 qPCR Primer Pairs, Mouse
LRIG1 Background Information
Leucine-rich repeats and immunoglobulin-like domains 1 (LRIG1) is a tumor suppressor and a negative regulator of several receptor tyrosine kinases.Leucine-rich repeats and immunoglobulin-like domains containing protein 1 (LRIG1) is an endogenous feedback regulator of receptor tyrosine kinases (RTKs) and was recently shown to inhibit growth of different types of malignancies.Leucine-rich repeats and immunoglobulin-like domains 1(LRIG1)is a kind of transmembrane glycoprotein,which is induced by epidermal growth factor (EGF),and develops inhibitory negative feedback by specific binding with epidermal growth factor receptor (EGFR). LRIG1 expression is broadly decreased in human cancer and in breast cancer and low expression of LRIG1 has been linked to decreased relapse-free survival.
Full Name
leucine-rich repeats and immunoglobulin-like domains 1
References
Shattuck DL, et al. (2007) LRIG1 Is a Novel Negative Regulator of the Met Receptor and Opposes Met and Her2 Synergy. Mol Cell Biol. 27 (5): 1934-46. Ledda F, et al. (2008) Lrig1 is an endogenous inhibitor of Ret receptor tyrosine kinase activation, downstream signaling, and biological responses to GDNF. J Neurosci. 28(1): 39-49. Hedman H, et al. (2002) Is LRIG1 a tumour suppressor gene at chromosome 3p14.3 Acta Oncol. 41(4): 352-4.